248 related articles for article (PubMed ID: 32499210)
1. The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors.
Friedlaender A; Liu SV; Passaro A; Metro G; Banna G; Addeo A
Clin Lung Cancer; 2020 Nov; 21(6):e539-e543. PubMed ID: 32499210
[TBL] [Abstract][Full Text] [Related]
2. Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.
Smit HJM; Aerts J; van den Heuvel M; Hiltermann TJN; Bahce I; Smit EF; Dingemans AC; Hendriks LE; Stigt JA; Schramel FMNH; van Tinteren H; Groen HJM;
Lung Cancer; 2020 Feb; 140():107-112. PubMed ID: 31911323
[TBL] [Abstract][Full Text] [Related]
3. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review.
Liu X; Xing H; Zhang H; Liu H; Chen J
Immunotherapy; 2021 Aug; 13(12):989-1000. PubMed ID: 34114477
[TBL] [Abstract][Full Text] [Related]
5. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
Reddy HG; Qin A; Kalemkerian GP
Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
[TBL] [Abstract][Full Text] [Related]
6. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
Konala VM; Madhira BR; Ashraf S; Graziano S
Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
[TBL] [Abstract][Full Text] [Related]
7. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
Zeng R; Liu F; Fang C; Yang J; Luo L; Yue P; Gao B; Dong Y; Xiang Y
Front Immunol; 2021; 12():724443. PubMed ID: 34777341
[TBL] [Abstract][Full Text] [Related]
8. Identification of Potential Prognostic and Predictive Biomarkers for Immune-Checkpoint Inhibitor Response in Small Cell Lung Cancer.
Gao C; Gu X; Chen Y; Zhou M; Jiang F; Zheng S
Med Sci Monit; 2021 Nov; 27():e932275. PubMed ID: 34719665
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes associated with corticosteroid use before chemoimmunotherapy in patients with advanced lung cancer.
Sorial MN; Huynh JP; Azzoli CG; Liauw JC; Brunault RD; Collins CM; Zullo AR
Eur J Cancer; 2021 Mar; 145():234-244. PubMed ID: 33431285
[TBL] [Abstract][Full Text] [Related]
10. Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer.
Yu L; Lai Q; Gou L; Feng J; Yang J
J Drug Target; 2021 Jan; 29(1):1-11. PubMed ID: 32700566
[TBL] [Abstract][Full Text] [Related]
11. Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
Cooper MR; Alrajhi AM; Durand CR
Am J Ther; 2018; 25(3):e349-e356. PubMed ID: 29722737
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of PD1/PDL1 blockade with platinum-based chemotherapy for extensive small cell lung cancer: A pooled analysis of randomized trials.
Messina C; Salati M; Messina M; Cattrini C; Merz V; Caffo O
Eur J Clin Invest; 2021 May; 51(5):e13483. PubMed ID: 33382454
[No Abstract] [Full Text] [Related]
13. Immunotherapy in Advanced Lung Cancer.
Huang J; Reckamp KL
Oncology (Williston Park); 2020 Jul; 34(7):272-279. PubMed ID: 32674216
[TBL] [Abstract][Full Text] [Related]
14. Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer.
Bar J; Ofek E; Barshack I; Gottfried T; Zadok O; Kamer I; Urban D; Perelman M; Onn A
Lung Cancer; 2019 Dec; 138():109-115. PubMed ID: 31683093
[TBL] [Abstract][Full Text] [Related]
15. Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice.
Steffen McLouth LE; Lycan TW; Levine BJ; Gabbard J; Ruiz J; Farris M; Grant SC; Pajewski NM; Weaver KE; Petty WJ
Clin Lung Cancer; 2020 May; 21(3):255-263.e4. PubMed ID: 31917067
[TBL] [Abstract][Full Text] [Related]
16. Evolving role of immunotherapy in small cell lung cancer.
Barrows ED; Blackburn MJ; Liu SV
Semin Cancer Biol; 2022 Nov; 86(Pt 3):868-874. PubMed ID: 35192928
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer.
Schlick B; Shields MD; Marin-Acevedo JA; Patel I; Pellini B
Curr Treat Options Oncol; 2022 Aug; 23(8):1104-1120. PubMed ID: 35716328
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitors in Small Cell Lung Cancer: Is It Also a Matter of Helios- Cells?
Mormile R
Pathol Oncol Res; 2020 Apr; 26(2):1355-1356. PubMed ID: 30927205
[No Abstract] [Full Text] [Related]
19. The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers.
Gelsomino F; Lamberti G; Parisi C; Casolari L; Melotti B; Sperandi F; Ardizzoni A
Cancer Treat Rev; 2019 Sep; 79():101887. PubMed ID: 31491661
[TBL] [Abstract][Full Text] [Related]
20. [Present and Future of Efficacy Biomarkers in Immune Checkpoint Inhibitors
of Small Cell Lung Cancer].
Yang Y; Wang Y
Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):897-903. PubMed ID: 32773012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]